Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis

Clinical and Experimental Immunology

Volumn 148, Issue 2, 2007, Pages 348-359

  Matsuda, C ^a   Ito, T ^a   Song, J ^a   Mizushima, T ^b   Tamagawa, H ^a   Kai, Y ^a   Hamanaka, Y ^c   Inoue, M ^c   Nishida, T ^a   Matsuda, H ^d   Sawa, Y ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Cardiology   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Everolimus; IFN ; Inflammatory bowel disease; Interleukin 10 knockout mice; mTOR inhibitor

Indexed keywords

EVEROLIMUS; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LAMINA PROPRIA; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; BODY WEIGHT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROHN DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; INTESTINAL MUCOSA; LYMPH NODES; LYMPHOCYTE COUNT; MALE; MICE; MICE, INBRED C57BL; SIROLIMUS; SPLEEN; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 34247108064     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03345.x     Document Type: Article

References (52)

1. Shanahan F. Crohn's disease. Lancet 2002; 359 (9300):62-9.
2. Scribano ML, Prantera C. Review article: medical treatment of active Crohn's disease. Aliment Pharmacol Ther 2002; 16 (Suppl. 4):35-9.
3. Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther 2002; 16 (Suppl. 4):40-7.
4. Forbes A. Review article: Crohn's disease - the role of nutritional therapy. Aliment Pharmacol Ther 2002; 16 (Suppl. 4):48-52.
5. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91 (3):423-33.
6. Parronchi P, Romagnani P, Annunziato F et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997; 150 (3):823-32.
7. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120 (3):622-35.
8. Nakase H, Okazaki K, Tabata Y et al. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther 2000; 292 (1):15-21.
9. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97 (12):2962-72.
10. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5 (2):119-33.
11. Ito H. Anti-interleukin-6 therapy for Crohn's disease. Curr Pharm Des 2003; 9 (4):295-305.
12. Ding C, Jones D. Technology evaluation: MRA, Chugai. Curr Opin Mol Ther 2003; 5 (1):64-9.
13. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol 2003; 98 (2):511-2.
14. Sandborn WJ. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology 1995; 109 (3):1001-3.
15. Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc 1992; 67 (10):981-90.
16. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93 (3):442-8.
17. Bousvaros A, Leichtner AM, Book L. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology 1996; 111 (1):237-43.
18. Bousvaros A, Wang A, Leichtner AM. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996; 23 (3):329-33.
19. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998; 93 (10):1860-6.
20. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43 (2):83-95.
21. Bierer BE, Hollander G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993; 5 (5):763-73.
22. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144 (1):251-8.
23. Lorber MI, Basadonna GP, Friedman AL et al. The evolving role of tor inhibitors for individualizing posttransplant immunosuppression. Transplant Proc 2001; 33 (7-8):3075-7.
24. Majewski M, Korecka M, Kossev P et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97 (8):4285-90.
25. Singh B, Read S, Asseman C. et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001; 182:190-200.
26. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003; 170 (8):3939-43.
27. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107 (3):1018-23.
28. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105 (12):4743-8.
29. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190 (7):995-1004.
30. Takahashi I, Kiyono H, Hamada S. CD4+ T-cell population mediates development of inflammatory bowel disease in T-cell receptor alpha chain-deficient mice. Gastroenterology 1997; 112 (6):1876-86.
31. Fujihashi K, McGhee JR, Kweon MN et al. gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med 1996; 183 (4):1929-35.
32. Iijima H, Takahashi I, Kishi D et al. Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. J Exp Med 1999; 190 (5):607-15.
33. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004; 172 (11):6519-23.
34. Mizushima T, Ito T, Kishi D et al. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 2004; 10 (3):182-92.
35. Berg DJ, Zhang J, Weinstock JV et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 2002; 123 (5):1527-42.
36. Imamura F, Shinkai K, Mukai M et al. rho-Mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion. Int J Cancer 1996; 65 (5):627-32.
37. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 1993; 75 (2):263-74.
38. Berg DJ, Davidson N, Kuhn R et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 98 (4):1010-20.
39. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998; 161 (6):3143-9.
40. Davidson NJ, Leach MW, Fort MM et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996; 184 (1):241-51.
41. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10-/- mice: an overview. J Leukoc Biol 1997; 61 (4):389-96.
42. Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta 7 integrin and mucosal address in cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997; 158 (5):2099-106.
43. Ludviksson BR, Strober W, Nishikomori R, Hasan SK, Ehrhardt RO. Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice. J Immunol 1999; 162 (8):4975-82.
44. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348 (1):24-32.
45. Ikenoue Y, Tagami T, Murata M. Development and validation of a novel IL-10 deficient cell transfer model for colitis. Int Immunopharmacol 2005; 5 (6):993-1006.
46. Assmann T, Homey B, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 2000; 47 (2-3):203-13.
47. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000; 47 (2-3):63-83.
48. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001; 7 (6):473-84.
49. MacDonald TT. Effector and regulatory lymphoid cells and cytokines in mucosal sites. Curr Top Microbiol Immunol 1999; 236:113-35.
50. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Invest Drugs 2002; 11 (12):1845-57.
51. Vitko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5 (10):2521-30.
52. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80 (6):749-58.